Bain Capital Life Sciences is at it again. Biotech’s go-to source for big-ticket financing rounds has stepped up to lead a $350 million series A round in Areteia Therapeutics, positioning the newly created startup to run phase 3 trials of an asthma candidate designed to have biologiclike efficacy in an oral dosage form.
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today reported further clinical data from its Phase 2 Exhale trial demonstrating oral dexpramipexole improves airflow obstruction in asthma as measured by FEV1, largely through its effect on FVC. Change in FVC was the dominant contributor to increases in FEV1, which suggests that by lowering eosinophils in the airway lumen, dexpramipexole may act to decrease mucus plugging and air trapping in small airways. As previously reported, dexpramipexole produced clinically meaningful increases in FEV1 across study arms and time points.
PITTSBURGH - ( BUSINESS WIRE ) - Knopp Biosciences LLC announced today that it has received a third year research grant from the US National Institutes of Health (NIH) to develop its novel opioid-free therapies Advance chronic pain management. The project is funded by the NIH Helping to End Addiction Long-term Initiative ( NIH HEAL Initiative ), which aims to improve chronic pain management, curb opioid use disorder and overdose rates, and achieve long-term cessation of opioid addiction.
Knopp Biosciences LLC today announced positive top-line results in a Phase 2 dose-ranging trial of the novel oral drug dexpramipexole in patients with moderate-to-severe eosinophilic asthma.
Knopp Biosciences LLC today reported further clinical and biomarker data demonstrating that reduction in eosinophil count by oral dexpramipexole significantly correlated with improved lung function in the positive Phase 2 EXHALE trial of dexpramipexole in patients with moderate-to-severe eosinophilic asthma. The data were presented in a late-breaking abstract session at the European Respiratory Society International Congress 2021.
Knopp Biosciences LLC rapporteerde vandaag verdere klinische en biomarkergegevens die aantonen dat vermindering van het aantal eosinofielen door oraal dexpramipexol significant correleerde met verbeterde longfunctie in de positieve fase 2 EXHALE-studie van dexpramipexol bij patiënten met matige tot ernstige eosinofiele astma. De gegevens werden gepresenteerd in een laat-brekende abstracte sessie op het European Respiratory Society International Congress 2021.
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma. The data were presented in a virtual poster session at the ATS 2021 International Conference.
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma. The data were presented in a virtual poster session at the ATS 2021 International Conference.
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced it will present detailed results of its positive Phase 2 dose-ranging EXHALE trial of the novel oral eosinophil-lowering drug dexpramipexole in patients with moderate-to-severe asthma in a virtual poster session at the ATS 2021 International Conference.
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC gab heute positive Ergebnisse einer Phase-2-Dosisfindungsstudie mit dem neuartigen oral verabreichten Medikament Dexpramipexol bei Patienten mit mittelschwerem bis schwerem eosinophilem Asthma bekannt.